255 related articles for article (PubMed ID: 33014867)
1. Preoperative Predictors of Biochemical Recurrence-Free Survival in High-Risk Prostate Cancer Following Radical Prostatectomy.
Nkengurutse G; Tian F; Jiang S; Wang Q; Wang Y; Sun W
Front Oncol; 2020; 10():1761. PubMed ID: 33014867
[No Abstract] [Full Text] [Related]
2. The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Biochemical Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy.
Wang S; Yang X; Yu Z; Du P; Sheng X; Cao Y; Yan X; Ma J; Yang Y
Front Oncol; 2022; 12():907625. PubMed ID: 35719913
[TBL] [Abstract][Full Text] [Related]
3. Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer.
Beauval JB; Roumiguié M; Filleron T; Benoit T; de la Taille A; Malavaud B; Salomon L; Soulié M; Ploussard G
BMC Urol; 2016 Jun; 16(1):26. PubMed ID: 27267988
[TBL] [Abstract][Full Text] [Related]
4. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Klaassen Z; Singh AA; Howard LE; Feng Z; Trock B; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Partin A; Han M; Freedland SJ
Cancer; 2015 May; 121(9):1414-21. PubMed ID: 25492369
[TBL] [Abstract][Full Text] [Related]
5. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
[TBL] [Abstract][Full Text] [Related]
6. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.
Lee H; Jeong SJ; Hong SK; Byun SS; Lee SE; Oh JJ
World J Urol; 2016 Jun; 34(6):821-7. PubMed ID: 26449784
[TBL] [Abstract][Full Text] [Related]
7. Pathological outcomes and biochemical recurrence-free survival after radical prostatectomy for high-risk prostate cancer in the Indian population.
Bijalwan P; Pooleri GK; Kalavampara SV; Bhat S; Thomas A; Sundar P; Laddha A
Indian J Urol; 2018; 34(4):260-267. PubMed ID: 30337780
[TBL] [Abstract][Full Text] [Related]
8. Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy.
Knipper S; Karakiewicz PI; Heinze A; Preisser F; Steuber T; Huland H; Graefen M; Tilki D
Urol Oncol; 2020 Apr; 38(4):184-190. PubMed ID: 31928867
[TBL] [Abstract][Full Text] [Related]
9. Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
Nagao K; Matsuyama H; Matsumoto H; Nasu T; Yamamoto M; Kamiryo Y; Baba Y; Suga A; Tei Y; Yoshihiro S; Aoki A; Shimabukuro T; Joko K; Sakano S; Takai K; Yamaguchi S; Akao J; Kitahara S;
Int J Clin Oncol; 2018 Aug; 23(4):757-764. PubMed ID: 29589154
[TBL] [Abstract][Full Text] [Related]
10. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
Ritch CR; You C; May AT; Herrell SD; Clark PE; Penson DF; Chang SS; Cookson MS; Smith JA; Barocas DA
Urology; 2014 Jun; 83(6):1309-15. PubMed ID: 24746665
[TBL] [Abstract][Full Text] [Related]
11. Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.
Pagano MJ; Whalen MJ; Paulucci DJ; Reddy BN; Matulay JT; Rothberg M; Scarberry K; Patel T; Shapiro EY; RoyChoudhury A; McKiernan J; Benson MC; Badani KK
Prostate; 2016 Feb; 76(2):226-34. PubMed ID: 26481325
[TBL] [Abstract][Full Text] [Related]
12. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
Choy B; Pearce SM; Anderson BB; Shalhav AL; Zagaja G; Eggener SE; Paner GP
Am J Surg Pathol; 2016 Oct; 40(10):1400-6. PubMed ID: 27379821
[TBL] [Abstract][Full Text] [Related]
14. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
[TBL] [Abstract][Full Text] [Related]
15. Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy.
Özsoy M; Moschini M; Fajkovic H; Soria F; Seitz C; Klatte T; Gust K; Briganti A; Karakiewicz PI; Roupret M; Kramer G; Shariat SF
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):100-105. PubMed ID: 29230007
[TBL] [Abstract][Full Text] [Related]
16. Role of inflammatory factors in prediction of Gleason score and its upgrading in localized prostate cancer patients after radical prostatectomy.
Wang S; Ji Y; Ma J; Du P; Cao Y; Yang X; Yu Z; Yang Y
Front Oncol; 2022; 12():1079622. PubMed ID: 36713540
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
18. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Predictors of Lymph Node Invasion and Biochemical Recurrence in High-risk Prostate Cancer.
Shida Y; Hakariya T; Mitsunari K; Matsuo T; Ohba K; Miyata Y; Sakai H
Cancer Diagn Progn; 2022; 2(1):49-54. PubMed ID: 35400005
[TBL] [Abstract][Full Text] [Related]
20. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
